Torsade de pointes associated with moxifloxacin: A rare but potentially fatal adverse eventLes torsades de pointe associées à la moxifloxacine : Une réaction indésirable rare, mais au potentiel fatal
References (11)
- et al.
In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome
Eur J Pharmacol
(2004) - et al.
The safety profile of the fluoroquinolones
Clin Ther
(2000) - et al.
An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study)
Am J Cardiol
(1992) Quinolone-induced QT interval prolongation: A not-sounexpected class effect
J Antimicrob Chemother
(2000)- et al.
Torsades de pointes associated with fluoroquinolones
Pharmacotherapy
(2002)
Cited by (46)
Rational synthesis of rare-earth lanthanum molybdate covered reduced graphene oxide nanocomposites for the voltammetric detection of Moxifloxacin hydrochloride
2022, BioelectrochemistryCitation Excerpt :Further, the MOF has been administered in several ways such as intravenously, orally and also 0.5% MOF has been used as eye drops for bacterial infection. However, over-dosage leads to several adverse side effects such as congestive heart failure, renal insufficiency [4,5], hematologic [6], acute polyarthritis [7], ocular hyperemia [8] and keratitis [9]. Therefore, MOF has drawn a greater interest to develop an easy and accurate method to quantify in biological samples.
Antimicrobial agents and torsades de pointes
2022, Torsades de PointesIn vivo analysis of the effects of intravenously as well as orally administered moxifloxacin on the pharmacokinetic and electrocardiographic variables along with its torsadogenic action in the chronic atrioventricular block cynomolgus monkeys
2020, Journal of Pharmacological SciencesCitation Excerpt :Moxifloxacin has been used as a positive control drug on performing QT/QTc studies for new drug candidates, since it possesses a favorable cardiac safety profile despite its QT-interval prolonging action.1,2 Indeed, torsade de pointes was induced neither in previous QT/QTc studies1–3 nor in phase II/III clinical trials4,5; however, there are several case reports describing that moxifloxacin induced torsade de pointes, in which patients were treated with 400 mg/body/day of oral or intravenous moxifloxacin.6–10 Importantly, these patients were confirmed to have such risk factors toward the drug-induced QT prolongation and torsade de pointes as hypertension, chronic renal failure, congestive heart failure, left ventricular dysfunction and coronary artery disease.7–10
Cardiac arrest among patients with infections: causes, clinical practice and research implications
2017, Clinical Microbiology and InfectionUse of FDSS/μCell imaging platform for preclinical cardiac electrophysiology safety screening of compounds in human induced pluripotent stem cell-derived cardiomyocytes
2016, Journal of Pharmacological and Toxicological MethodsCitation Excerpt :We do not really understand why prolongation induces EADs in our system. Rare cases of QT prolongation by therapeutically-relevant doses of moxifloxacin, associated with TdPs, have been reported in the clinic (e.g. Altin et al., 2007; Sherazi, DiSalle, Daubert, & Shah, 2008). Limited by our current dataset, we could not explain the discrepancy of effects of ranolazine that induced EADs in iCells, but no clinical TdPs.